Skip to content
Webe Honey – Lifestyle
Home
Sample Page
Author:
Inhibrx Biosciences, Inc.
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
June 15, 2026
Inhibrx Reports First Quarter 2026 Financial Results
May 14, 2026
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
May 11, 2026
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
May 8, 2026
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
April 21, 2026
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
April 20, 2026
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
March 19, 2026